All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
During The 6th World Congress on Controversies in Multiple Myeloma (COMy), Francesca Gay, University of Torino, Torino, IT, and our Steering Committee member Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, debated on whether anti-CD38 antibody-based induction therapy should be used in all patients with multiple myeloma (MM) prior to transplant. They reviewed the data from various studies to address the issue, highlighting the CASSIOPEIA and GRIFFIN trials, and focused on daratumumab, which was the only approved anti-CD38 antibody up until recently.1
The Multiple Myeloma Hub has been focusing on the ongoing potential of monoclonal antibodies in MM as an editorial theme; find more information on these agents discussed here.
Mohamad Mohty started his discussion by describing the historic data which showed the importance of induction therapy prior to transplantation for patients with MM:
For the last 3 years, triple VD-based regiments have been the standard of care for induction therapy, but recent additions of anti-CD38 antibodies to these triple regimens have further increased CR rates.
The addition of daratumumab to induction therapies resulted in deeper, better quality responses. Mohamad Mohty argues that these are the main reasons to defend that anti-CD38 antibody-based induction therapy should be used in all patients with MM prior to transplant, especially as there are no additional safety concerns.
Francesca Gay began by explaining that if we want to see if it is worth using anti-CD38 antibodies as induction therapy, then we must first consider the goals of induction therapy; which are to achieve a rapid and deep response with a tolerable regimen that allows for adequate stem-cell collection.
Randomized trials using four cycles of the current standard of care treatment; proteasome inhibitors in combination with immunomodulatory agents such as VCD, VTD, and VRD, all showed deep responses (≥ very good partial response rates) of about 30–60%.
When a fourth agent, the anti-CD38 antibody daratumumab, was added, the rate of deep responses increased to about 65-73% in the case of VTD and VRD based quadruplets.
Furthermore, triplet combinations of the second-generation proteasome inhibitor, carfilzomib, in combination with lenalidomide and dexamethasone (KRD) could also provide a 70% ≥ very good partial response rates, suggesting anti-CD38 therapy may no longer be required.
However, Francesca Gay noted that these comparisons were limited because they compare data from different trials. Therefore, she focused on the CASSIOPEIA and GRIFFIN studies, which directly compared triplet combinations with and without daratumumab. These studies showed a higher rate of high-quality responses, specifically at post-consolidation, but also after induction with the quadruplet combination compared with the triplet.
The rate of Grade 3/4 hematologic toxicities was higher in the quadruplet combinations compared with triplet combinations:
However, the Grade 3/4 infections and lymphopenia were comparable across the arms. Therefore, suggesting that the regiments were manageable.
These trials also showed that a similar number of stem cells could be collected from both the triplet or quadruplet combinations, and the neutrophil engraftment was similar. However, the quadruplet combinations required a higher use of Plerixafor (CASSIOPEIA: 7% vs 22% VTD vs Dara-VTD; GRIFFIN: 55% vs 70%, VRD vs Dara-VRD)
Francesca Gay then made further points that it may be unnecessary to use anti-CD38 antibodies for all patients:
She then debated whether a combination of all the most effective drugs should be used at first-line treatment or whether another treatment strategy would be better to optimize patient outcomes.
The debaters agreed that the use of anti-CD38 antibodies as induction regiments seem to be beneficial. However, more data is required to determine if this is beneficial for all patients or for selected subgroups; and whether their use would have a better outcome at the relapse setting for different subsets of patients with MM.
In a poll conducted by the Multiple Myeloma Hub on Twitter shortly after the debate, voters largely agreed that anti-CD38 antibody-based therapies have demonstrated efficacy in patients with MM and should be routinely integrated into induction therapies (Figure 1).
Figure 1. Results of the Multiple Myeloma Hub poll: Anti-CD38 antibody-based therapies have demonstrated efficacy in patients with MM, but should they be routinely integrated into induction therapies?
Follow these links for a further summary of the results of the CASSIOPEIA and GRIFFIN studies
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox